Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, …

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …

Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia (AML) do
not achieve complete remission with intensive induction therapy and are therefore …

Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity …

Background Mutations occur in several genes in cytogenetically normal acute myeloid
leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (…

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an …

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Background In patients with acute myeloid leukemia (AML), the presence or absence of
recurrent cytogenetic aberrations is used to identify the appropriate therapy. However, the …

To assess the prognostic relevance of mutations in the NPM1 gene encoding a nucleocytoplasmic
shuttle protein in younger adults with acute myeloid leukemia (AML) and normal …

To assess the prognostic relevance of activating mutations of theFLT3 gene in homogeneously
treated adults 16 to 60 years of age with acute myeloid leukemia (AML) and normal …